Research News

09/21/2020

Cleveland Clinic Study Finds No Association Between Influenza Vaccine and COVID-19 Risk

Using patient data from Cleveland Clinic’s COVID-19 registry, Dr. Zein found that receiving the flu vaccine does not increase risk for COVID-19 or worsen associated disease outcomes, suggesting it is safe and advisable to receive the influenza vaccine this flu season.

In a new article published online ahead of press in the Journal of Clinical and Translational Science, researchers from Cleveland Clinic report that receiving the influenza vaccine does not increase a person’s risk for contracting COVID-19 or worsen associated morbidity or mortality.

Led by Joe Zein, MD, a practicing pulmonologist in the Respiratory Institute and lead author on the study, the research team analyzed more than 13,000 patients tested for COVID-19 at Cleveland Clinic (Ohio and Florida locations) between early March and mid-April of this year.

Comparing those who had received unadjuvanted influenza vaccines in the fall or winter of 2019 (4,138 patients) against those who did not received the vaccine (9,082 patients) revealed that influenza vaccination was not associated with increased COVID-19 incidence or disease severity, including risk for hospitalization, admission to the intensive care unit or mortality.

“Our findings suggest that we should proceed as usual with our vaccination strategy for global influenza this flu season,” said Dr. Zein. “Getting the annual flu vaccine remains the best safeguard against the influenza virus—both for yourself and the people around you.”

Since much is still unknown about the possible outcomes of concurrent SARS-CoV-2 (the virus that causes COVID-19) and influenza infection—including disease pathology and burden to the healthcare system—researchers and clinicians believe that the population’s adherence to widespread and early flu vaccination while researchers continue to collect data will help to mitigate the risk of simultaneous viral infections and epidemics/pandemics.

“We have already seen the stress that COVID-19 can put on our hospitals and resources,” said Dr. Zein. “While we’re not yet sure how flu season will affect COVID-19 susceptibility and infections, we strongly advise people to get their influenza vaccines, both for their individual health and the collective health of our care systems.”

This study is the latest to utilize data from patients enrolled in Cleveland Clinic’s COVID-19 Registry, which includes all individuals tested at Cleveland Clinic for the disease, not just those that test positive. Cleveland Clinic was one of the first organizations to develop a data registry and biobank for the emergent disease. Data from the registry has already been used in several landmark COVID-19 studies, including those that have led to the development of models that can predict a patient’s likelihood of testing positive for COVID-19 and being hospitalized due to COVID-19.

Serpil Erzurum, MD, chair of Cleveland Clinic’s Lerner Research Institute and a practicing pulmonologist in the Respiratory Institute, was a co-author on the study.

Featured Experts

Serpil Erzurum, MD

Staff
Chair, Lerner Research Institute
Chief Research & Academic Officer, Cleveland Clinic
Lab Profile

Related News Articles

Cleveland Clinic Appoints Ted Ross, PhD, as Global Director of Vaccine Development

In this newly created role, he will lead the development of novel vaccine platforms for a variety of infectious diseases, including influenza, HIV and COVID-19.

Podcast: Vaccine Research for Head and Neck Cancers

Dr. Natalie Silver joins the Cancer Advances podcast to talk about head and neck cancers and the treatment barriers we are trying to overcome.

Researchers Open Clinical Trial for Triple-Negative Breast Cancer Vaccine

Dr. Tuohy and his research team will begin vaccinating patients in a phase I trial to study how their triple-negative breast cancer vaccine immunizes against the protein alpha-lactalbumin.